» Articles » PMID: 17555831

Curcumin Reverses Breast Tumor Exosomes Mediated Immune Suppression of NK Cell Tumor Cytotoxicity

Overview
Specialties Biochemistry
Biophysics
Date 2007 Jun 9
PMID 17555831
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

An important characteristic of tumors is that they at some point in their development overcome the surveillance of the immune system. Tumors secrete exosomes, multivesicular bodies containing a distinct set of proteins that can fuse with cells of the circulating immune system. Purified exosomes from TS/A breast cancer cells, but not non-exosomal fractions, inhibit (at concentrations of nanograms per ml protein) IL-2-induced natural killer (NK) cell cytotoxicity. The dietary polyphenol, curcumin (diferuloylmethane), partially reverses tumor exosome-mediated inhibition of natural killer cell activation, which is mediated through the impairment of the ubiquitin-proteasome system. Exposure of mouse breast tumor cells to curcumin causes a dose-dependent increase in ubiquitinated exosomal proteins compared to those in untreated TS/A breast tumor cells. Furthermore, exosomes isolated from tumor cells pretreated with curcumin have a much attenuated inhibition of IL-2 stimulated NK cell activation. Jak3-mediated activation of Stat5 is required for tumor cytotoxicity of IL-2 stimulated NK cells. TS/A tumor exosomes strongly inhibit activation of Stat5, whereas the tumor exosomes isolated from curcumin-pretreated tumor cells have a lowered potency for inhibition of IL-2 stimulated NK cell cytotoxicity. These data suggest that partial reversal of tumor exosome-mediated inhibition of NK cell tumor cytotoxicity may account for the anti-cancer properties of curcumin.

Citing Articles

The theragnostic advances of exosomes in managing leukaemia.

Ghosh S, Dey A, Chakrabarti A, Bhuniya T, Indu N, Hait A J Cell Mol Med. 2024; 28(23):e70052.

PMID: 39659020 PMC: 11632122. DOI: 10.1111/jcmm.70052.


Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial.

Judith P, Maureen B, Melanie P, Fabrice K, Isabelle V, Pascale D Health Sci Rep. 2024; 7(9):e70052.

PMID: 39286738 PMC: 11403303. DOI: 10.1002/hsr2.70052.


Application of Photodynamic Therapy in Cardiology.

Wanczura P, Aebisher D, Klosowicz M, Mysliwiec A, Dynarowicz K, Bartusik-Aebisher D Int J Mol Sci. 2024; 25(6).

PMID: 38542180 PMC: 10969994. DOI: 10.3390/ijms25063206.


The Combination of Bioavailable Concentrations of Curcumin and Resveratrol Shapes Immune Responses While Retaining the Ability to Reduce Cancer Cell Survival.

Focaccetti C, Palumbo C, Benvenuto M, Carrano R, Melaiu O, Nardozi D Int J Mol Sci. 2024; 25(1).

PMID: 38203402 PMC: 10779126. DOI: 10.3390/ijms25010232.


Phytochemicals as Immunomodulatory Molecules in Cancer Therapeutics.

Paudel S, Mishra N, Agarwal R Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139779 PMC: 10746110. DOI: 10.3390/ph16121652.


References
1.
Chun K, Park K, Lee J, Kang M, Surh Y . Inhibition of mouse skin tumor promotion by anti-inflammatory diarylheptanoids derived from Alpinia oxyphylla Miquel (Zingiberaceae). Oncol Res. 2002; 13(1):37-45. DOI: 10.3727/096504002108747944. View

2.
Osada T, Clay T, Woo C, Morse M, Lyerly H . Dendritic cell-based immunotherapy. Int Rev Immunol. 2006; 25(5-6):377-413. DOI: 10.1080/08830180600992456. View

3.
Keum Y, Han S, Chun K, Park K, Park J, Lee S . Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat Res. 2003; 523-524:75-85. DOI: 10.1016/s0027-5107(02)00323-8. View

4.
Aggarwal B, Kumar A, Bharti A . Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23(1A):363-98. View

5.
Kim B, Lee H, Park S, Lee S, Karpova T, McNally J . Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor beta signaling by binding to Smad7 and promoting its degradation. Mol Cell Biol. 2004; 24(6):2251-62. PMC: 355855. DOI: 10.1128/MCB.24.6.2251-2262.2004. View